Clinical Trial: Long Term Safety Assessment of SER120 in Patients With Nocturia
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Phase III Open-Label Extension Study to Investigate the Safety of SER120 Nasal Spray Formulations in Patients With Nocturia Completing Study SPC-SER120-DB1-200901 or Stu
Brief Summary: The hypothesis of this study is that SER120 is safe and well tolerated for use in nocturic patients.
Detailed Summary:
Sponsor: Serenity Pharmaceuticals, Inc.
Current Primary Outcome: safety evaluation of SER120 in terms of laboratory and clinical assessments [ Time Frame: 11 month study ]
Original Primary Outcome: safety evaluation of SER120 in terms of laboratory and clinical assessments
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Serenity Pharmaceuticals, Inc.
Dates:
Date Received: September 18, 2009
Date Started: August 2009
Date Completion:
Last Updated: January 27, 2014
Last Verified: January 2014